Pain Processing:

How Omega-3 fatty acids (EPA and DHA) Impact Pain Processing

Omega-3 fatty acids (EPA and DHA) exert therapeutic effects across all levels of the pain processing pathway through both direct actions and through their conversion to specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins. These mechanisms address the 4 pathological processes central to the Pain Processing treatment paradigm: Systemic Inflammation, Neuroinflammation, Oxidative Stress and Mitochondrial Dysfunction.

See:

     How Nutraceuticals Impact Pain Processing

  1. How Acetyl-L-Carnitine (ALC) Impacts Pain Processing
  2. How Alpha-Lipoic Acid (ALA) impacts pain processing
  3. How Boswellia Impacts Pain Processing
  4. How CoQ10 Impacts Pain Processing
  5. How Curcumin Impacts Pain Processing
  6. How Magnesium Impacts Pain Processing
  7. How Melatonin Impacts Pain Processing
  8. How Omega-3 fatty acids (EPA and DHA) Impact Pain Processing
  9. How N-Acetyl Cysteine (NAC) Impacts Pain Processing
  10. How Nicotinamide Riboside (NR) Impacts Pain Processing
  11. How PEA (Palmitoylethanolamide) Impacts Pain Processing
  12. How Quercetin Impacts Pain Processing
  13. How Resveratrol Impacts Pain Processing
  14. How Sulforaphane (SFN): Impacts Pain Processing
  15. How Taurine Impacts Pain Processing

 

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

 

 See (On this Page):

 

How Omega-3 fatty acids (EPA and DHA) Impact Pain Processing

Omega-3 fatty acids (EPA and DHA) exert therapeutic effects across all levels of the pain processing pathway through both direct actions and through their conversion to specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins. These mechanisms address the 4 pathological processes central to the Pain Processing treatment paradigm: Systemic Inflammation, Neuroinflammation, Oxidative Stress and Mitochondrial Dysfunction.

Omega-3 fatty acids also provide unique analgesic properties distinct from  other nutraceuticals such as ALC and curcumin.

Local Activity in the joint vs Pain Processing

Supplementing with omega-3 fatty acids EPA and DHA doses up to 3000 mg per day has demonstrated symptomatic benefit for osteoarthritis, including early improvement in pain and stiffness. These fatty acids have also been demonstrated to reduce pain due to its effects on pain processing.

Based on the evidence, pain processing mechanisms—particularly direct neuronal effects and specialized pro-resolving mediator (SPM) generation—are most likely responsible for the early symptomatic improvement within the first 60 days of omega-3 supplementation, rather than local joint anti-inflammatory effects.

In contrast, local joint effects require longer timeframes. Preclinical studies show that cartilage protection and synovial cytokine modulation require 12 weeks of dietary omega-3 enrichment to demonstrate structural benefits.

The Levels, of Pain Processing can be organized as follows:

  • Level 1: Peripheral Nociception (Pain Receptor Transduction): Activation and Sensitization
  • Level 2: Primary Afferent Transmission to Spinal Cord
  • Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)
  • Level 4: Ascending Spinal Pathways and Supraspinal Processing
  • Level 5: Thalamic and Cortical Processing and Pain Perception
  • Level 6: Descending Pain Modulation

 

Level 1: Peripheral Nociception (Pain Receptor Transduction): Activation and Sensitization

At the peripheral level, omega-3 fatty acids modulate nociceptor function through multiple mechanisms. EPA and DHA directly interact with TRPV1 channels on primary afferent neurons. Notably, EPA and DHA exhibit differential effects: DHA acts as a TRPV1 agonist (potentially inducing desensitization), while EPA more effectively inhibits capsaicin-evoked TRPV1 responses and reduces capsaicin-evoked pain behavior in mice.[3] This competitive inhibition of vanilloid agonist responses occurs at physiological concentrations (1-10 µM).[3]

EPA also targets a novel molecular mechanism: it strongly and reversibly inhibits vesicular nucleotide transporter (VNUT) at an IC₅₀ of only 67 nM, acting as an allosteric modulator.[4] VNUT is essential for vesicular storage and release of ATP in purinergic transmission. By inhibiting ATP release from neurons, EPA attenuates both neuropathic and inflammatory pain without affecting basal nociception—and this analgesic effect was stronger than existing neuropathic pain drugs with fewer side effects.[4]

Omega-3 supplementation also accelerates peripheral nerve regeneration after injury. In mice with partial sciatic nerve ligation, EPA/DHA concentrate prevented mechanical allodynia and thermal hypernociception, increased GAP43 expression (a marker of axonal regeneration), and increased the total number of myelinated fibers in the sciatic nerve.[5] This regenerative effect was accompanied by reduced ATF-3 expression in DRG neurons, indicating decreased neuronal stress.[5]

Level 2: Primary Afferent Transmission

  • Omega-3 fatty acids protect primary afferent neurons through anti-inflammatory and neurotrophic mechanisms. In models of spinal cord injury, dietary omega-3 enrichment led to robust accumulation of novel N-acyl ethanolamine precursors in neural tissue, including docosahexaenoyl ethanolamine (DHEA), docosapentaenoyl ethanolamine (DPEA), and eicosapentaenoyl ethanolamine (EPEA)—and tissue levels of these metabolites correlated significantly with the antihyperalgesic phenotype.[6]

    The antinociceptive effects of EPA and DHA in diabetic neuropathic pain are mediated through opioid system activation. Intrathecal administration of µ-opioid receptor antagonist (CTOP) completely prevented the acute analgesic effect of fish oil, EPA, or DHA, suggesting that omega-3s engage endogenous opioid mechanisms.[7][8]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

The spinal cord dorsal horn represents a critical site of omega-3 action for pain modulation, primarily through suppression of neuroinflammation:

  • Microglial Modulation: Intrathecal DHA injection blocks carrageenan-induced pain hypersensitivity for more than 6 hours by inhibiting microglia-mediated neuroinflammation.[9] DHA reduces microglial activation, phosphorylation of p38 MAPK, and production of pro-inflammatory cytokines (TNF-α, IL-1β) in the L4-5 spinal cord.[9] In cultured microglia, DHA dose-dependently reduces LPS-induced production of cytokines (TNF-α, IL-1β, IL-6) and chemokines (CCL2, CCL3, CXCL10).[9]

    Astrocyte Modulation: DHA treatment reduces reactive astrocyte numbers (GFAP-positive cells) in the spinal cord dorsal horn superficial lamina, decreases substance P-immunopositive fibers, and reduces nNOS-positive neurons—all markers of central sensitization.[10]

    Prevention of Central Neuropathic Pain: In spinal cord injury models, intravenous DHA administration prevented central neuropathic pain development when given early, and partially abolished already-established pain when given later.[6] At both spinal (epicenter and L5 dorsal horns) and supraspinal (anterior cingulate cortex) levels, DHA potently suppressed microglial and astrocyte activation.[6] These effects were mediated through peroxisome proliferator-activated receptors (PPARs) and retinoid X receptors, and through the DHA metabolite docosahexaenoyl ethanolamide.[6]

    SIRT1-Mediated Mechanisms: Omega-3 PUFAs suppress microglial inflammatory responses through SIRT1 pathway activation. EPA and DHA enhance NAMPT (nicotinamide phosphoribosyltransferase) expression, increase cellular NAD⁺ levels, and activate SIRT1 deacetylase activity.[11] This leads to deacetylation of HMGB1, preventing its nuclear-to-cytoplasmic translocation and extracellular secretion, thereby inhibiting HMGB1-mediated NF-κB pathway activation.[12]

    Level 4: Ascending Spinal Pathways

Omega-3 fatty acids reduce the magnitude of nociceptive signals transmitted via ascending pathways by decreasing dorsal horn hyperexcitability. The reduction in p38 MAPK phosphorylation in projection neurons decreases aberrant signal amplification.[6][9]

Additionally, omega-3s reduce inositol levels in the spinal cord—metabolites that are positively correlated with thermal hyperalgesia and serve as biomarkers of chronic neuropathic pain.

Level 5: Thalamic and Cortical Processing

Omega-3 fatty acids cross the blood-brain barrier and exert direct effects on supraspinal pain processing centers:

TRPV1 Pathway Modulation: In fibromyalgia models, EPA significantly attenuates overexpression of TRPV1 signaling pathway elements in the thalamus, medial prefrontal cortex, somatosensory cortex, anterior cingulate cortex, and cerebellum.[13] This modulation of TRPV1 in ascending pain pathway structures correlates with reversal of mechanical allodynia and thermal hyperalgesia.[13]

Cerebellar Effects: EPA alleviates fibromyalgia-like pain by modulating microglia, astrocytes, and TLR4 signaling in the cerebellum.[14] EPA reduces elevated levels of microglial/astrocyte markers and neurotransmitters such as HMGB1 and S100B in cerebellar regions CB5-7.[14]

Neurotransmitter Modulation: Omega-3 fatty acids modulate brain monoamine systems critical to pain perception:[15][16][17]

    1. Serotonin: EPA increases serotonin release from presynaptic neurons by reducing E2 series prostaglandins; DHA influences serotonin receptor action by increasing cell membrane fluidity in postsynaptic neurons; vitamin D (which synergizes with omega-3s) activates tryptophan hydroxylase 2 for serotonin synthesis[15]
    2. Dopamine: Omega-3 supplementation increases dopamine and its metabolites (DOPAC, 3-MT, HVA) in the nucleus accumbens; increases tyrosine hydroxylase-positive cells in the ventral tegmental area[16]
    3. Norepinephrine: Modulates noradrenergic transmission; alleviates stress-induced increases in NE levels[18]

Level 6: Descending Pain Modulation

Omega-3 fatty acids support descending inhibitory pathways through multiple mechanisms:

  • Omega-3 fatty acids support descending inhibitory pathways through multiple mechanisms:

    Monoaminergic Enhancement: By increasing serotonergic and dopaminergic neurotransmission, omega-3s enhance the function of descending inhibitory pathways from the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM).[15][16] Omega-9 fatty acids (which share some mechanisms with omega-3s) have been shown to facilitate descending inhibitory antinociception after spinal cord injury.[19]

    TRPV1 Modulation in PAG: EPA and DHA reverse stress-induced decreases in TRPV1 and related molecules in the PAG, a key structure for descending pain modulation.[20]

Specialized Pro-Resolving Mediators (SPMs):  The Unique Omega-3 Advantage

A distinguishing feature of omega-3 fatty acids is their enzymatic conversion to specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins—which possess potent analgesic properties:[1][2][21]

• Resolvin D1 (RvD1) and Resolvin E1 (RvE1): Suppress inflammatory cytokines, modulate TRP channels, and resolve inflammation through specific G protein-coupled receptors

• Neuroprotectin D1 (NPD1): Derived from DHA, NPD1 potently inhibits capsaicin-induced TRPV1 current with an IC₅₀ of 0.4 nM—approximately 500 times more potent than AMG9810, a commonly used TRPV1 antagonist. Spinal injection of NPD1 at very low doses (0.1-10 ng) blocks spinal LTP and reduces TRPV1-dependent inflammatory pain.[22]

• Maresin 1 (MaR1): Modulates pain pathways through suppression of inflammatory cytokines and interactions with immune cells[23][24][25]

SPMs exert their anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor, increasing PGE₂-induced cAMP formation and converting macrophage EP4 receptors from anti-phagocytic to pro-phagocytic—a central mechanism of inflammation resolution.[1]

 

Systemic Inflammation, Neuroinflammation, Oxidative Stress and Mitochondrial Dysfunction

Systemic Inflammation, Neuroinlammation, Oxidative Stress and Mitochondrial Dysfunction are 4 pathological processes/conditions that contribute to chronic pain by creating a cycle of tissue damage, immune cell activation, and pain amplification. By disrupting normal cellular physiology, these conditions also contribute to the development and progression of chronic diseases, including diabetes, heart disease, stroke, chronic kidney and liver disease, rheumatoid arthritis, cancer and Alzheimer’s.

  1. Systemic inflammation (SI) is a widespread inflammatory response throughout the body, triggered by infection, injury, stress and other conditions. It involves activation of the immune system with the release of pro-inflammatory compounds that contribute to chronic pain and lead to other health issues. Symptoms of SI include increased pain, fatigue, cognitive problems, depression, decreased motivation for physical activity and, in severe cases, organ dysfunction. While inflammation is a natural part of the healing process, chronic or excessive SI contributes to the development of heart disease, diabetes, and autoimmune disorders like rheumatoid arthritis.
  2. Neuroinflammation (NI), a component of systemic inflammation, is inflammation within the central nervous system (brain and spinal cord). SI releases inflammatory compounds that cross into the brain and spinal cord that activate immune cells causing NI and contributes to the progression of acute to chronic pain. NI is characterized by activation of immune cells (glial cells and astrocytes) in the nervous system that release inflammatory chemicals like cytokines, proteases, and free radicals such as reactive oxygen (ROS), and nitrogen species (RNS). When these immune cells remain activated, neuroinflammation persists and drives chronic pain.
  3. Oxidative stress (OS) is an imbalance of excessive “oxidants” (“oxidizing” or chemically active agents (including ROS and NOS) obtained from the diet or produced by the body coupled with insufficient “antioxidants,” the compounds that neutralize oxidants. Excessive oxidants damage nerve cells and other tissues causing and maintaining pain. Antioxidants are manufactured by the body, but sufficient dietary intake of antioxidants is critical for good health. OS and chronic SI co-exist and feed each other, damaging tissues in a vicious cycle that further worsens pain.
  4. Mitochondrial Dysfunction (MD). Mitochondria are organelles found in cells that function as the “power stations” of cells in that they process food into energy. In addition to providing energy, they play a major role in maintaining antioxidants to combat OS and SI. Because mitochondria impact the metabolism of all cells, they play a huge role in general health. Impairment of mitochondrial function (dysfunction) contributes to many conditions including chronic pain, obesity, migraines, fibromyalgia, diabetes, heart disease and neurodegenerative diseases like Alzheimers. In MD, energy production goes down and fatigue develops along with impaired physical functioning, even if more calories are ingested. MD is the hallmark of conditions such as obesity and fibromyalgia. Mitochondrial dysfunction leads to the metabolic impairment that is found in many chronic diseases including depression, bipolar disorders and premature aging.

Integration of Pain Processing with the 4 Pathological Processes

Pathological Process

Omega-3 Mechanism

Pain Pathway Impact

Systemic Inflammation

Reduces TNF-α, IL-1β, IL-6; decreases prostaglandin E2 synthesis; generates anti-inflammatory SPMs (resolvins, protectins, maresins); inhibits COX-2 and 5-LOX pathways

Decreases peripheral sensitization; reduces inflammatory mediator-induced nociceptor activation

[1][2]

Neuroinflammation

Suppresses microglial activation via p38 MAPK inhibition; promotes M1→M2 microglial polarization via SIRT1-HMGB1/NF-κB pathway; reduces astrocyte reactivity (GFAP); decreases spinal chemokine production (CCL2, CCL3, CXCL10)

Prevents/reverses central sensitization; reduces glial-mediated synaptic facilitation at spinal and supraspinal levels

|[9][11][12][26]

Oxidative Stress

Attenuates ROS activation; upregulates Bcl-2 and Bcl-xL anti-apoptotic proteins; increases glutathione levels; reduces cleaved caspase-3; prevents 7-ketocholesterol-induced mitochondrial dysfunction

Protects DRG neurons, spinal neurons, and cortical neurons from oxidative damage

 

|[27][28]

Mitochondrial Dysfunction

Promotes mitophagy via Pink1/Parkin pathway; increases Drp1 and LC3 expression; improves mitochondrial dynamics; restores Complex I+II and IV activity; increases ATP production; generates NPD1-like metabolites that enhance mitochondrial function

Restores neuronal bioenergetics; clears damaged mitochondria; supports nerve regeneration

 

[29][30][31]

–

Clinical Evidence

A 2025 meta-analysis of 41 RCTs (n=3,759) found that omega-3 fatty acids produce a moderate, clinically significant reduction in chronic pain intensity (SMD -0.55; 95% CI -0.76 to -0.34).[32] Pain relief was noticeable at 1 month (SMD -0.27) and improved by 6 months (SMD -0.83). Interestingly, lower doses (≤1.35 g/day) were more effective than higher doses, and benefits were significant for rheumatoid arthritis, migraine, and mixed chronic pain conditions.[32] An earlier meta-analysis of 46 intervention studies similarly found omega-3 supplementation moderately improves chronic pain (pooled SMD -0.40), with the largest effects for dysmenorrhea and omega-3 specifically (vs. mixed PUFAs).[33]

Comparison with ALC and Curcumin: Complementary Mechanisms

1. Primary spinal mechanism

  • ALC: Epigenetic mGlu2 upregulation (inhibits glutamate release) [34][35]
  • Curcumin: HAT inhibition; inflammasome suppression; M1→M2 shift [37[36]
  • Omega-3 (EPA/DHA) p38 MAPK inhibition; SIRT1-HMGB1/NF-κB; SPM generation

2. TRP channel effects

  • ALC: Indirect[1]
  • Curcumin: TRPV1 antagonism[10]
  • Omega-3 (EPA/DHA) TRPV1 modulation (EPA inhibits, DHA activates/desensitizes); NPD1 potent TRPV1 inhibitor[11][12]

3. Unique mechanism

  • ALC: Acetyl group donor; long-lasting epigenetic analgesia[1][2][13]
  • Curcumin: Microglial phenotype switching; NLRP3/NALP1 inhibition[3][4][5][14]
  • Omega-3 (EPA/DHA): VNUT inhibition (blocks ATP release); SPM generation; opioid system activation[15][16][17][6]

4. Duration of effect

  • ALC: Persists 37 days post-discontinuation[2]
  • Curcumin: Requires continued administration[18][19][20]
  • Omega-3 (EPA/DHA): Time-dependent improvement (peaks at 6 months)[21])

These complementary mechanisms suggest strong potential for synergy when omega-3 fatty acids are combined with ALC and curcumin in the nutraceutical paradigm—each targeting distinct molecular pathways while converging on the common goals of reducing neuroinflammation, oxidative stress, and central sensitization.

Key Mechanistic Distinctions

The three nutraceuticals demonstrate distinct but complementary mechanisms:

1. Acetyl-L-Carnitine (ALC) produces analgesia through epigenetic upregulation of mGlu2 receptors in the spinal cord, with effects persisting for at least 37 days after drug withdrawal—significantly longer than conventional analgesics like pregabalin, amitriptyline, or tramadol. This long-lasting effect is associated with increased levels of acetylated histone H3 bound to the Grm2 gene promoter in dorsal root ganglia. ALC also acts as a donor of acetyl groups to NF-κB p65/RelA, enhancing transcription of the GRM2 gene encoding mGlu2 receptors.[2][13]

2. Curcumin demonstrates analgesic efficacy through anti-inflammatory and antioxidant mechanisms, with meta-analyses showing significant pain reduction (SMD -0.57) that appears independent of dose and treatment duration. Curcumin specifically inhibits the NLRP3 inflammasome by preventing K⁺ efflux and disturbing downstream events including ASC oligomerization and speckle formation. It also suppresses NLRP3 inflammasome activation by inducing autophagy, upregulating LC3-I and LC3-II while downregulating p62 expression in the spinal cord. Unlike ALC, curcumin’s effects require continued administration, with clinical trials typically showing benefits during active treatment periods of 4-12 weeks.[20][3][5][18][19]

3. Omega-3 fatty acids show a unique time-dependent pattern of pain relief, with effects noticeable at 1 month (SMD -0.27) and progressively improving to peak efficacy at 6 months (SMD -0.83). This temporal pattern likely reflects the gradual accumulation of omega-3s in cell membranes and the time required for SPM biosynthesis and resolution of chronic inflammation.[21][6][22]

Rationale for Combination Therapy

The complementary mechanisms of these three nutraceuticals provide a strong rationale for combination therapy:

• Temporal complementarity: ALC provides rapid-onset analgesia with long-lasting epigenetic effects that persist weeks after discontinuation; curcumin offers immediate anti-inflammatory action during active treatment through NLRP3 inflammasome inhibition; omega-3s provide progressive, sustained improvement over months through SPM generation and membrane incorporation.[2][3][4][21][6]

• Mechanistic complementarity: ALC targets glutamatergic transmission via mGlu2 receptor upregulation; curcumin targets inflammasome pathways and microglial phenotype; omega-3s target purinergic transmission (VNUT inhibition), SPM generation, and opioid system activation.[1][2][3][5][14][15][16][6]

• Pathway convergence: All three ultimately reduce neuroinflammation, oxidative stress, and central sensitization through distinct upstream mechanisms, potentially producing additive or synergistic effects.[1][6][4]

Summary

Omega-3 fatty acids (EPA and DHA) represent a unique therapeutic approach to chronic pain that operates across all levels of the pain processing pathway. Their mechanisms include:

1. Direct receptor modulation: TRPV1 channel modulation and VNUT inhibition at peripheral nociceptors[11][15]

2. Opioid system engagement: Activation of endogenous opioid mechanisms for acute analgesia[16][17]

3. Neuroinflammation suppression: Inhibition of microglial and astrocyte activation via p38 MAPK, SIRT1-HMGB1/NF-κB pathways at spinal and supraspinal levels[7][8][9]

4. SPM generation: Conversion to resolvins, protectins, and maresins that actively resolve inflammation and provide potent analgesia[12][6][22][23]

5. Neurotransmitter modulation: Enhancement of serotonergic and dopaminergic transmission supporting descending inhibitory pathways[24][25]

6. Nerve regeneration: Promotion of axonal regeneration and myelination in injured peripheral nerves[26]

7. Mitochondrial support: Enhancement of mitophagy and mitochondrial dynamics[27][28][29]

When combined with ALC (epigenetic glutamatergic modulation) and curcumin (inflammasome inhibition), omega-3 fatty acids complete a comprehensive nutraceutical approach that addresses the four pathological processes—systemic inflammation, neuroinflammation, oxidative stress, and mitochondrial dysfunction—through complementary temporal and mechanistic profiles.

References

  1. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Ji RR. Annual Review of Pharmacology and Toxicology. 2023;63:273-293. doi:10.1146/annurev-pharmtox-051921-084047.
  2. The Mechanisms of Specialized Pro-Resolving Mediators in Pain Relief: Neuro-Immune and Neuroglial Regulations. Chen Y, Wu X, Li J, et al. Frontiers in Immunology. 2025;16:1634724. doi:10.3389/fimmu.2025.1634724.
  3. TRPV1 Is a Novel Target for Omega-3 Polyunsaturated Fatty Acids. Matta JA, Miyares RL, Ahern GP. The Journal of Physiology. 2007;578(Pt 2):397-411. doi:10.1113/jphysiol.2006.121988.
  4. Vesicular Nucleotide Transporter Is a Molecular Target of Eicosapentaenoic Acid for Neuropathic and Inflammatory Pain Treatment. Kato Y, Ohsugi K, Fukuno Y, et al. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(30):e2122158119. doi:10.1073/pnas.2122158119.
  5. Long-Chain Omega-3 Fatty Acids Supplementation Accelerates Nerve Regeneration and Prevents Neuropathic Pain Behavior in Mice. Silva RV, Oliveira JT, Santos BLR, et al. Frontiers in Pharmacology. 2017;8:723. doi:10.3389/fphar.2017.00723.
  6. Fatty Acid Suppression of Glial Activation Prevents Central Neuropathic Pain After Spinal Cord Injury. Georgieva M, Wei Y, Dumitrascuta M, et al. Pain. 2019;160(12):2724-2742. doi:10.1097/j.pain.0000000000001670.
  7. Acute Antinociceptive Effect of Fish Oil or Its Major Compounds, Eicosapentaenoic and Docosahexaenoic Acids on Diabetic Neuropathic Pain Depends on Opioid System Activation. Redivo DDB, Jesus CHA, Sotomaior BB, Gasparin AT, Cunha JM. Behavioural Brain Research. 2019;372:111992. doi:10.1016/j.bbr.2019.111992.
  8. The Antihyperalgesic Effect of Docosahexaenoic Acid in Streptozotocin-Induced Neuropathic Pain in the Rat Involves the Opioidergic System. Landa-Juárez AY, Pérez-Severiano F, Castañeda-Hernández G, Ortiz MI, Chávez-Piña AE. European Journal of Pharmacology. 2019;845:32-39. doi:10.1016/j.ejphar.2018.12.029.
  9. Spinal Injection of Docosahexaenoic Acid Attenuates Carrageenan-Induced Inflammatory Pain Through Inhibition of Microglia-Mediated Neuroinflammation in the Spinal Cord. Lu Y, Zhao LX, Cao DL, Gao YJ. Neuroscience. 2013;241:22-31. doi:10.1016/j.neuroscience.2013.03.003.
  10. Docosahexaenoic Acid Attenuates the Early Inflammatory Response Following Spinal Cord Injury in Mice: In-Vivo and in-Vitro Studies. Paterniti I, Impellizzeri D, Di Paola R, et al. Journal of Neuroinflammation. 2014;11:6. doi:10.1186/1742-2094-11-6.
  11. Omega-3 Polyunsaturated Fatty Acids Suppress the Inflammatory Responses of Lipopolysaccharide-Stimulated Mouse Microglia by Activating SIRT1 Pathways. Inoue T, Tanaka M, Masuda S, et al. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids. 2017;1862(5):552-560. doi:10.1016/j.bbalip.2017.02.010.
  12. Omega-3 Polyunsaturated Fatty Acid Attenuates the Inflammatory Response by Modulating Microglia Polarization Through SIRT1-mediated Deacetylation of the HMGB1/NF-κB Pathway Following Experimental Traumatic Brain Injury. Chen X, Chen C, Fan S, et al. Journal of Neuroinflammation. 2018;15(1):116. doi:10.1186/s12974-018-1151-3.
  13. Eicosapentaenoic Acid Modulates Transient Receptor Potential V1 Expression in Specific Brain Areas in a Mouse Fibromyalgia Pain Model. Liao HY, Yen CM, Hsiao IH, Hsu HC, Lin YW. International Journal of Molecular Sciences. 2024;25(5):2901. doi:10.3390/ijms25052901.
  14. Eicosapentaenoic Acid Alleviates Fibromyalgia-Like Pain by Modulating Microglia, Astrocytes, and Toll-Like Receptor 4 Signaling in the Mice Cerebellum. Hsiao IH, Hsu HC, Lin IY, Chuang KT, Lin YW. Nutritional Neuroscience. 2025;:1-12. doi:10.1080/1028415X.2025.2518210.
  15. Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, Part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior. Patrick RP, Ames BN. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2015;29(6):2207-22. doi:10.1096/fj.14-268342.
  16. Participation of the Nucleus Accumbens Dopaminergic System in the Antidepressant-Like Actions of a Diet Rich in Omega-3 Polyunsaturated Fatty Acids. Takeuchi E, Yamada D, Suzuki S, et al. PloS One. 2020;15(3):e0230647. doi:10.1371/journal.pone.0230647.
  17. Possible Antidepressant Mechanisms of Omega-3 Polyunsaturated Fatty Acids Acting on the Central Nervous System. Zhou L, Xiong JY, Chai YQ, et al. Frontiers in Psychiatry. 2022;13:933704. doi:10.3389/fpsyt.2022.933704.
  18. Dietary of N-3 Polyunsaturated Fatty Acids Influence Neurotransmitter Systems of Rats Exposed to Unpredictable Chronic Mild Stress. Yang R, Zhang MQ, Xue Y, Yang R, Tang MM. Behavioural Brain Research. 2019;376:112172. doi:10.1016/j.bbr.2019.112172.
  19. The Role of Omega-3 and Omega-9 Fatty Acids for the Treatment of Neuropathic Pain After Neurotrauma. Galán-Arriero I, Serrano-Muñoz D, Gómez-Soriano J, et al. Biochimica Et Biophysica Acta. Biomembranes. 2017;1859(9 Pt B):1629-1635. doi:10.1016/j.bbamem.2017.05.003.
  20. Transient Receptor Potential V1 (TRPV1) Modulates the Therapeutic Effects for Comorbidity of Pain and Depression: The Common Molecular Implication for Electroacupuncture and Omega-3 Polyunsaturated Fatty Acids. Lin YW, Chou AIW, Su H, Su KP. Brain, Behavior, and Immunity. 2020;89:604-614. doi:10.1016/j.bbi.2020.06.033.
  21. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?. Chávez-Castillo M, Ortega Á, Cudris-Torres L, et al. International Journal of Molecular Sciences. 2021;22(19):10370. doi:10.3390/ijms221910370.
  22. Resolving TRPV1- And TNF-α-mediated Spinal Cord Synaptic Plasticity and Inflammatory Pain With Neuroprotectin D1. Park CK, Lü N, Xu ZZ, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2011;31(42):15072-85. doi:10.1523/JNEUROSCI.2443-11.2011.
  23. The Pro-Resolving Lipid Mediator Maresin 1 Ameliorates Pain Responses and Neuroinflammation in the Spared Nerve Injury-Induced Neuropathic Pain: A Study in Male and Female Mice. Teixeira-Santos L, Martins S, Sousa T, Albino-Teixeira A, Pinho D. PloS One. 2023;18(6):e0287392. doi:10.1371/journal.pone.0287392.
  24. The Role of Maresins in Inflammatory Pain: Function of Macrophages in Wound Regeneration. Hwang SM, Chung G, Kim YH, Park CK. International Journal of Molecular Sciences. 2019;20(23):E5849. doi:10.3390/ijms20235849.
  25. The Specialised Pro-Resolving Lipid Mediator Maresin 1 Reduces Inflammatory Pain With a Long-Lasting Analgesic Effect. Fattori V, Pinho-Ribeiro FA, Staurengo-Ferrari L, et al. British Journal of Pharmacology. 2019;176(11):1728-1744. doi:10.1111/bph.14647.
  26. Omega-3 Polyunsaturated Fatty Acid Supplementation Attenuates Microglial-Induced Inflammation by Inhibiting the HMGB1/TLR4/NF-κB Pathway Following Experimental Traumatic Brain Injury. Chen X, Wu S, Chen C, et al. Journal of Neuroinflammation. 2017;14(1):143. doi:10.1186/s12974-017-0917-3.
  27. Prevention of 7-Ketocholesterol-Induced Overproduction of Reactive Oxygen Species, Mitochondrial Dysfunction and Cell Death With Major Nutrients (Polyphenols, Ω3 and Ω9 Unsaturated Fatty Acids) of the Mediterranean Diet on N2a Neuronal Cells. Yammine A, Nury T, Vejux A, et al. Molecules (Basel, Switzerland). 2020;25(10):E2296. doi:10.3390/molecules25102296.
  28. Enriched Endogenous Omega-3 Polyunsaturated Fatty Acids Protect Cortical Neurons From Experimental Ischemic Injury. Shi Z, Ren H, Luo C, et al. Molecular Neurobiology. 2016;53(9):6482-6488. doi:10.1007/s12035-015-9554-y.
  29. Docosahexaenoic Acid Alleviates Brain Damage by Promoting Mitophagy in Mice With Ischaemic Stroke. Sun E, Zhang J, Deng Y, et al. Oxidative Medicine and Cellular Longevity. 2022;2022:3119649. doi:10.1155/2022/3119649.
  30. Omega-3 Fatty Acid-Type Docosahexaenoic Acid Protects Against Aβ-Mediated Mitochondrial Deficits and Pathomechanisms in Alzheimer’s Disease-Related Animal Model. Park YH, Shin SJ, Kim HS, et al. International Journal of Molecular Sciences. 2020;21(11):E3879. doi:10.3390/ijms21113879.
  31. Omega-3 Polyunsaturated Fatty Acids Improve Mitochondrial Dysfunction in Brain Aging–Impact of BCL-2 and NPD-1 Like Metabolites. Afshordel S, Hagl S, Werner D, et al. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2015;92:23-31. doi:10.1016/j.plefa.2014.05.008.
  32. Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
  33. Polyunsaturated Fatty Acids and Chronic Pain: A Systematic Review and Meta-Analysis. Prego-Dominguez J, Hadrya F, Takkouche B. Pain Physician. 2016 Nov-Dec;19(8):521-535.
  34. A Review of Therapeutic Potentials of Turmeric (Curcuma Longa) and Its Active Constituent, Curcumin, on Inflammatory Disorders, Pain, and Their Related Patents. Razavi BM, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Phytotherapy Research : PTR. 2021;35(12):6489-6513. doi:10.1002/ptr.7224.
  35. Acetyl-L-Carnitine in Chronic Pain: A Narrative Review. Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Pharmacological Research. 2021;173:105874. doi:10.1016/j.phrs.2021.105874. 
  36. Analgesia Induced by the Epigenetic Drug, L-Acetylcarnitine, Outlasts the End of Treatment in Mouse Models of Chronic Inflammatory and Neuropathic Pain. Notartomaso S, Mascio G, Bernabucci M, et al. Molecular Pain. 2017;13:1744806917697009. doi:10.1177/1744806917697009.

 

Omega-3 Fatty Acids (EPA/DHA): Pain Processing Effects vs. Direct Tissue-Modifying Effects

   Pain Processing Effects:

EPA directly inhibits vesicular nucleotide transporter (VNUT) at IC₅₀ of 67 nM, blocking ATP release in purinergic pain transmission—this represents a novel molecular target distinct from anti-inflammatory effects.[11] EPA/DHA-derived specialized pro-resolving mediators (SPMs: resolvins, protectins, maresins) modulate neuroinflammation and inhibit central/peripheral sensitization.[12] EPA modulates TRPV1 expression in pain-processing brain regions (thalamus, prefrontal cortex, somatosensory cortex, anterior cingulate cortex) in fibromyalgia models.[13] A 2025 meta-analysis of 41 RCTs (n=3,759) found omega-3s produced moderate pain reduction (SMD = -0.55), with benefits increasing over time (SMD = -0.27 at 1 month to -0.83 at 6 months).[14]

   Direct Tissue-Modifying Effects:

Omega-3s demonstrate cartilage-protective effects in preclinical models. N-3 PUFAs alleviate obesity-related OA progression and protect cartilage by inhibiting the HMGB1-RAGE/TLR4 signaling pathway, with decreased expression of inflammatory proteins in articular cartilage.[15] EPA restores inflammation-induced changes in chondrocyte mechanics by suppressing the NF-κB p65/CD44 signaling pathway, alleviating cartilage degeneration in mouse OA models.[16] Omega-3s reduce pro-inflammatory cytokine cascades and promote anti-inflammatory oxylipin production, with antiapoptotic and antiangiogenic effects contributing to reduced OA development.[17][18]

However, clinical evidence for structural modification is limited. A 2024 JAMA RCT of krill oil (2g/day) in 262 participants with knee OA found no significant difference in effusion-synovitis (a structural surrogate) at 24 weeks, despite modest pain improvements.[19] The study concluded that krill oil did not significantly reduce knee pain compared to placebo, challenging earlier positive findings from smaller trials.

Mechanism

Pain Processing

Tissue Modification

References

VNUT inhibition (IC₅₀ 67 nM)

Blocks purinergic pain transmission

None

[1]

SPM synthesis (resolvins, maresins)

Inhibits central/peripheral sensitization

Promotes inflammation resolution

[2]

TRPV1 modulation in brain regions

Reduces ascending pain signals

None

[3]

HMGB1-RAGE/TLR4 inhibition

Indirect

Cartilage protection (preclinical)

[4]

NF-κB p65/CD44 pathway suppression

Reduces inflammatory signaling

Restores chondrocyte mechanics

[5]

Nerve regeneration (↑GAP43, ↑myelinated fibers)

Reduces neuropathic pain

Promotes axonal regeneration

[6]

 

   References

  1. Effectiveness of Boswellia and Boswellia Extract for Osteoarthritis Patients: A Systematic Review and Meta-Analysis. Yu G, Xiang W, Zhang T, et al. BMC Complementary Medicine and Therapies. 2020;20(1):225. doi:10.1186/s12906-020-02985-6.
  2. A Standardized Boswellia Serrata Extract Shows Improvements in Knee Osteoarthritis Within Five Days-a Double-Blind, Randomized, Three-Arm, Parallel-Group, Multi-Center, Placebo-Controlled Trial. Majeed A, Majeed S, Satish G, et al. Frontiers in Pharmacology. 2024;15:1428440. doi:10.3389/fphar.2024.1428440.
  3. Efficacy and Safety of Boswellia Serrata and Apium Graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial. Vaidya N, Agarwal R, Dipankar DG, et al. Pharmaceutical Research. 2025;42(2):249-269. doi:10.1007/s11095-025-03818-2.
  4. A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of a Novel Boswellia Serrata Extract in the Management of Osteoarthritis of the Knee. Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. Phytotherapy Research : PTR. 2019;33(5):1457-1468. doi:10.1002/ptr.6338.
  5. Extract Containing 30% 3-Acetyl-11-Keto-Boswellic Acid Attenuates Inflammatory Mediators and Preserves Extracellular Matrix in Collagen-Induced Arthritis. Majeed M, Nagabhushanam K, Lawrence L, et al. Frontiers in Physiology. 2021;12:735247. doi:10.3389/fphys.2021.735247.
  6. Frankincense: Systematic Review. Ernst E. BMJ (Clinical Research Ed.). 2008;337:a2813. doi:10.1136/bmj.a2813.
  7. Efficacy and Safety of Curcumin and Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Zeng L, Yang T, Yang K, et al. Frontiers in Immunology. 2022;13:891822. doi:10.3389/fimmu.2022.891822.
  8. The Efficacy of Curcumin in Relieving Osteoarthritis: A Meta-Analysis of Meta-Analyses. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, et al. Phytotherapy Research : PTR. 2024;38(6):2875-2891. doi:10.1002/ptr.8153.
  9. Curcumin for the Clinical Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Fan Y, Yi Z, Mao S, et al. Frontiers in Immunology. 2025;16:1726157. doi:10.3389/fimmu.2025.1726157.
  10. Effect of Curcumin on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Kou H, Huang L, Jin M, et al. Frontiers in Immunology. 2023;14:1121655. doi:10.3389/fimmu.2023.1121655.
  11. Vesicular Nucleotide Transporter Is a Molecular Target of Eicosapentaenoic Acid for Neuropathic and Inflammatory Pain Treatment. Kato Y, Ohsugi K, Fukuno Y, et al. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(30):e2122158119. doi:10.1073/pnas.2122158119.
  12. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?. Chávez-Castillo M, Ortega Á, Cudris-Torres L, et al. International Journal of Molecular Sciences. 2021;22(19):10370. doi:10.3390/ijms221910370.
  13. Eicosapentaenoic Acid Modulates Transient Receptor Potential V1 Expression in Specific Brain Areas in a Mouse Fibromyalgia Pain Model. Liao HY, Yen CM, Hsiao IH, Hsu HC, Lin YW. International Journal of Molecular Sciences. 2024;25(5):2901. doi:10.3390/ijms25052901.
  14. Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
  15. N-3 Polyunsaturated Fatty Acids Alleviate the Progression of Obesity-Related Osteoarthritis and Protect Cartilage Through Inhibiting the HMGB1-RAGE/TLR4 Signaling Pathway. Xiong T, Huang S, Wang X, et al. International Immunopharmacology. 2024;128:111498. doi:10.1016/j.intimp.2024.111498.
  16. Eicosapentaenoic Acid Restores Inflammation-Induced Changes in Chondrocyte Mechanics by Suppressing the NF-κB P65/Cd44 Signaling Pathway and Attenuates Osteoarthritis. Yang Q, Wu J, Huang S, et al. Experimental & Molecular Medicine. 2025;:10.1038/s12276-025-01529-7. doi:10.1038/s12276-025-01529-7.
  17. Omega-3 Supplementation and Its Effects on Osteoarthritis. Shawl M, Geetha T, Burnett D, Babu JR. Nutrients. 2024;16(11):1650. doi:10.3390/nu16111650.
  18. The Role of Nutraceuticals in Osteoarthritis Prevention and Treatment: Focus on N-3 PUFAs. Oppedisano F, Bulotta RM, Maiuolo J, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:4878562. doi:10.1155/2021/4878562.
  19. Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial. Laslett LL, Scheepers LEJM, Antony B, et al. JAMA. 2024;331(23):1997-2006. doi:10.1001/jama.2024.6063.
  20. Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain. Viana MDM, Lauria PSS, Lima AA, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2420. doi:10.3390/antiox11122420.
  21. Molecular Mechanisms of Lipoic Acid Modulation of T-Type Calcium Channels in Pain Pathway. Lee WY, Orestes P, Latham J, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2009;29(30):9500-9. doi:10.1523/JNEUROSCI.5803-08.2009.
  22. Alpha-Lipoic Acid Modulates the Diabetes Mellitus-Mediated Neuropathic Pain via Inhibition of the TRPV1 Channel, Apoptosis, and Oxidative Stress in Rats. Yazğan B, Yazğan Y, Nazıroğlu M. Journal of Bioenergetics and Biomembranes. 2023;55(3):179-193. doi:10.1007/s10863-023-09971-w.
  23. Alpha-Lipoic Acid Downregulates TRPV1 Receptor via NF-κB and Attenuates Neuropathic Pain in Rats With Diabetes. Zhang BY, Zhang YL, Sun Q, et al. CNS Neuroscience & Therapeutics. 2020;26(7):762-772. doi:10.1111/cns.13303.
  24. Alpha-Lipoic Acid Reduces Nociception by Reducing Oxidative Stress and Neuroinflammation in a Model of Complex Regional Pain Syndrome Type I in Mice. Rodrigues P, Cassanego GB, Peres DS, et al. Behavioural Brain Research. 2023;459:114790. doi:10.1016/j.bbr.2023.114790.
  25. Evaluation of the Analgesic Effect of Ɑ-Lipoic Acid in Treating Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. Pharmacological Research. 2022;177:106075. doi:10.1016/j.phrs.2022.106075.
  26. Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
  27. Efficacy and Safety of Antioxidant Treatment With Α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 Trial. Ziegler D, Low PA, Litchy WJ, et al. Diabetes Care. 2011;34(9):2054-60. doi:10.2337/dc11-0503.
  28. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Hsieh RY, Huang IC, Chen C, Sung JY. Nutrients. 2023;15(16):3634. doi:10.3390/nu15163634.

 

 

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.